-
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
•
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE), has entered into a research collaboration with Quotient Therapeutics, a Cambridge, Massachusetts-based biotech firm. The partnership will focus on analyzing somatic mutations in diseased patient tissue, with a goal of uncovering new therapeutic approaches for…
-
Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit
•
LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the US, has once again failed to find a buyer for its China operations, despite valuing the unit at over USD 1 billion. The company, known for manufacturing the painkiller OxyContin, has engaged in at least…
-
Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines
•
BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical Co., Ltd and Chengdu Institute of Biological Products Co., Ltd., part of Sinopharm, are on the path to priority review for their respective medical innovations. Ruidio’s Technetium [99mTc] hydrazine nicotinamide polyethylene glycol bicyclic RGD peptide…
-
Jiangsu Simcere and AnDiConBio’s Anti-Influenza Drug ADC189 Doses First Patient in Phase III Study
•
JIANGSU—In a significant development for the pharmaceutical industry, Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), in collaboration with AnDiConBio, has initiated a Phase III clinical study for their anti-influenza drug, ADC189. This study marks a crucial step in the advancement of pediatric treatment options, with the first patient dosed in…
-
Sino Biopharmaceutical’s Anlotinib-Penpulimab Combo Meets Milestone in Phase III HCC Study
•
HONG KONG—Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the successful completion of a pre-set interim analysis in its Phase III clinical study. The study combines anlotinib with penpulimab as a first-line treatment for advanced hepatocellular carcinoma (HCC), achieving the optimal efficacy thresholds for…
-
Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development
•
CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100 million in a recent financing round spearheaded by Hygeia Capital. The syndicate of investors includes CAS STAR, Chengdu Biocity Jingchuang Equity Investment Fund, CS Ventures, and other prominent firms. The newly raised capital is earmarked…
-
Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China
•
NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a significant regulatory milestone with the National Medical Products Administration’s (NMPA) marketing approval for its JETSTREAM vascular plaque rotary cutting system. This development marks a significant step forward in the treatment of peripheral arterial disease (PAD)…
-
China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety
•
BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device Management Law of the People’s Republic of China,” seeking public input until September 28. The law aims to regulate the entire spectrum of medical device activities, from research to supervision, within the nation’s borders. The…
